Skip to main content
Fraiser Kansteiner on Muck Rack

Fraiser Kansteiner

Verified
New York
As seen in: Fierce Biotech, Fierce Pharma, Questex Media Group, EIN News, Veterans Today, NewsBreak, Fierce Healthcare, The Top Line, fiercebiotechresearch.com, Our Community Now, UAE Industry Times, Borderless Executive Live: The Podcast
Fraiser Kansteiner is a staff writer at Fierce Pharma. He covers topics such as manufacturing, drug delivery and COVID-19.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Fraiser

Contact Fraiser, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Novo, Alvotech face continued FDA scrutiny at plants tied to recent FDA rejections

|
By Fraiser Kansteiner Verified
| Fierce Pharma Verified
From Indiana to Iceland, the FDA this week disclosed concerns raised during recent visits to a pair of manufacturing sites with troubled regulatory histories. In the U.S., Novo Nordisk has been dinged for record-keeping shortfalls, lackluster control procedures over production processes and more at the Bloomington, Indiana, facility it acquired by way of Catalent when its parent, Novo Holdings, acquired the CDMO in 2024.
Open in Who Shared Issue with article?

Sanofi opens new chapters in Pfizer, Moderna mRNA patent litigation sagas

|
By Fraiser Kansteiner Verified
| Fierce Pharma Verified
As Pfizer and Moderna have tied off certain threads in their separate webs of mRNA patent litigation, Sanofi has opened a new front to challenge the companies’ blockbuster COVID-19 vaccines.
Open in Who Shared Issue with article?

Buzzy Veradermics shows its oral minoxidil can tackle female pattern hair loss, too

|
By Fraiser Kansteiner Verified
| Fierce Pharma Verified
With a midstage peek at the data on Veradermics’ oral formulation of the molecule behind the ubiquitous hair regrowth treatment Rogaine, analysts are feeling increasingly confident that the New Haven, Connecticut-based company is a cut above the rest when it comes to the opportunity in the under-tapped market for female pattern hair loss.
Open in Who Shared Issue with article?
See all 2,439 licensed articles (3,464 Total)